Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
FDA+ channel feed
What controversy? Eli Lilly plots Alzheimer's BLA filing later this year as FDA taps more anti-amyloid drugs as breakthroughs
4 years ago
FDA slams Incyte's PD-1 over single-arm study, low response and trial deaths
4 years ago
Y-mAbs pushes back re-submission of its neuroblastoma BLA to end of 2021
4 years ago
New FDA documents show internal dissent on Aduhelm approval
4 years ago
Yescarta goes to China as Fosun Kite nabs historic first CAR-T OK
4 years ago
China
Cell/Gene Tx
With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline
4 years ago
Deals
Woodcock defends Biogen's new Alzheimer's drug, says it has more supportive data than many past accelerated approvals
4 years ago
Consortium of 5 drug regulators plot path to increase harmonization through 2024
4 years ago
New DARPA-like NIH agency preps for reality as E&C unveils bipartisan Cures 2.0 draft bill
4 years ago
Biogen's new Alzheimer's drug serves as a rallying cry for drug pricing reforms
4 years ago
Pharma
Spring regulatory agenda: What’s coming soon-ish from the FDA
4 years ago
After roller-coaster week, CRL forces a reckoning on Orphazyme investors — inflated shares plummet
4 years ago
Sen. Manchin to Biden: Don't nominate Woodcock for FDA commissioner
4 years ago
Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation
4 years ago
Medicaid commission to Congress: Increase rebates for accelerated approval drugs
4 years ago
Pharma
Opinion: CMS needs to do FDA’s job and limit the use of Biogen’s pricey new Alzheimer’s drug
4 years ago
Opinion
New Alzheimer's drug approval fallout: Public Citizen seeks removal of FDA's Woodcock, Cavazzoni and Dunn
4 years ago
FDA’s Cavazzoni calls for adcomms to ‘get back to the substance’
4 years ago
Recall report: Another drugmaker is pulling its version of metformin off shelves after a carcinogen scare
4 years ago
Manufacturing
A snakebit biotech receives second CRL for reformulated pain med, potentially putting the kibosh on its chances
4 years ago
75M vaccine doses wasted: FDA spells out Emergent facility deficiencies at length in new memo
4 years ago
Coronavirus
FDA authorizes about 10M J&J vaccine doses, trashes 60M more from troubled Emergent plant
4 years ago
Coronavirus
An expensive watch, shell companies and fake invoices: How two Israeli traders tapped into a $100M global biotech insider trading ring
4 years ago
People
Harvard’s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'
4 years ago
First page
Previous page
106
107
108
109
110
111
112
Next page
Last page